1. Home
  2. MBOT vs STTK Comparison

MBOT vs STTK Comparison

Compare MBOT & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MBOT
  • STTK
  • Stock Information
  • Founded
  • MBOT 2010
  • STTK 2016
  • Country
  • MBOT United States
  • STTK United States
  • Employees
  • MBOT N/A
  • STTK N/A
  • Industry
  • MBOT Medical/Dental Instruments
  • STTK Biotechnology: Pharmaceutical Preparations
  • Sector
  • MBOT Health Care
  • STTK Health Care
  • Exchange
  • MBOT Nasdaq
  • STTK Nasdaq
  • Market Cap
  • MBOT 128.9M
  • STTK 119.0M
  • IPO Year
  • MBOT N/A
  • STTK 2020
  • Fundamental
  • Price
  • MBOT $1.91
  • STTK $2.02
  • Analyst Decision
  • MBOT Strong Buy
  • STTK Hold
  • Analyst Count
  • MBOT 1
  • STTK 5
  • Target Price
  • MBOT $12.00
  • STTK $3.00
  • AVG Volume (30 Days)
  • MBOT 1.9M
  • STTK 113.1K
  • Earning Date
  • MBOT 11-12-2025
  • STTK 11-06-2025
  • Dividend Yield
  • MBOT N/A
  • STTK N/A
  • EPS Growth
  • MBOT N/A
  • STTK N/A
  • EPS
  • MBOT N/A
  • STTK N/A
  • Revenue
  • MBOT N/A
  • STTK $1,000,000.00
  • Revenue This Year
  • MBOT N/A
  • STTK N/A
  • Revenue Next Year
  • MBOT $1,107.73
  • STTK N/A
  • P/E Ratio
  • MBOT N/A
  • STTK N/A
  • Revenue Growth
  • MBOT N/A
  • STTK N/A
  • 52 Week Low
  • MBOT $0.93
  • STTK $0.69
  • 52 Week High
  • MBOT $4.67
  • STTK $2.71
  • Technical
  • Relative Strength Index (RSI)
  • MBOT 36.04
  • STTK 53.75
  • Support Level
  • MBOT $1.70
  • STTK $1.88
  • Resistance Level
  • MBOT $2.20
  • STTK $2.22
  • Average True Range (ATR)
  • MBOT 0.13
  • STTK 0.17
  • MACD
  • MBOT 0.02
  • STTK 0.01
  • Stochastic Oscillator
  • MBOT 40.40
  • STTK 64.01

About MBOT Microbot Medical Inc.

Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: